Stem (STEM)
(Delayed Data from NYSE)
$0.62 USD
+0.04 (6.03%)
Updated Aug 29, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Brokerage Reports
Microbot Medical Inc. [STEM]
Reports for Purchase
Showing records 41 - 60 ( 84 total )
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Effected; Reiterate Buy with Adjusted $18 Price Target
Provider: Rodman & Renshaw, Co.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Effected; Reiterate Buy with Adjusted $18 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With a Buy
Provider: Rodman & Renshaw, Co.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Strategic Realignment Keeps Spinal Cord Indication; Reiterate Buy with Adjusted $1.50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Solid Cervical Spinal Cord Injury Data; Assuming Coverage with Buy and $2.10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Highlights from the Meeting on the Mesa: Looking Beyond Stem Cells in Regenerative Medicine
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Update: Positive Dry AMD Findings; Reiterate Buy Rating and PT $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIN C
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Early Signs of Activity Despite Disparate Findings; Reiterate Buy Rating and PT of $1
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: LIN C
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
The Promise of Self-Renewing Cells; Initiating with Buy and a PT of $1
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: LIN C
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
2Q''14 EPS; Two Controlled Phase II Starts by YE14
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Market Outperform and a $7.00 one-year price target.
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
3Q12 Results; Steps Towards Clinical Ramp Up; Maintain Neutral; PT to $2
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
Important Patent Win for Liver Cells; Intriguing Potential Opportunities
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Microbot Medical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.